Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ivosidenib versus placebo in IDH1-mutant conventional chondrosarcoma
jRCT2061240032Phase 3Recruiting
- Sponsor
- Servier
- Start
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in chondrosarcoma comparing Ivosidenib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Jun 2024; status: recruiting.
02
Drugs
ivosidenib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on jRCT2061240032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240032.